Age-related macular degeneration
Authors:
I. Fišer
Authors‘ workplace:
EVROPSKÁ OČNÍ KLINIKA LEXUM, PRAHA
4
Published in:
Čes Ger Rev 2010; 8(1-2): 33-39
Overview
Age-related macular degeneration (AMD) is the most common cause of vision loss in developed countries in people older than 55 years. The wet form of this disease is the cause of severe vision impairment in 90 percent of patients. AMD develops as a result of an interaction between genetic and lifestyle factors. The key mechanism in the development of wet AMD is the growth of new vessels, stimulated by the vascular endothelial growth factor (VEGF). The treatment of choice is, therefore, the use of anti-VEGF agents administered as intravitreal injections. International clinical studies are evaluating new AMD treatments. It is necessary to start the treatment early, before severe visual impairment occurs.
Key words:
age-related macular degeneration – anti-VEGF – Avastin
Sources
1. Congdon N, O’Colmain B, Klaver CC et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122 (4): 477–485.
2. Friedman DS, O’Colmain BJ, Muñoz B et al. Eye Diseases Prevalence Research Group. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol 2004; 122 (4): 564–572. Abstract.
3. Ferris FL 3rd, Fine SL, Hyman L. Agerelated macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102 (11): 1640–1642.
4. Green WR. Histopathology of agerelated macular degeneration. Mol Vis 1999; 5: 27–36.
5. Khan JC, Shahid H, Thurlby DA et al. Age related macular degeneration and sun exposure, iris colour, and skin sensitivity to sunlight. Br J Ophthalmol 2006; 90: 29–32. Abstract.
6. Smith W, Assink J, Klein R et al. Risk factors for agerelated macular degeneration: Pooled findings from three continents. Ophthalmology 2001; 108 (4): 697–704. Abstract.
7. Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of agerelated macular degeneration. Science 2005; 308 (5 720): 419–421. Abstract.
8. Seddon JM, Ajani UA, Superduto RD et al. Dietary carotenoids, vitamins A, C and E and advanced agerelated macular degeneration. Eye Disease CaseControl Study Group. JAMA 1994; 272: 1413–1420. Abstract.
9. van Leuwen R, Boekhoorn S, Vingerling JR et al. Dietary intake of antioxidants and risk of agerelated macular degeneration. JAMA 2005; 294 (24): 3101–3107. Abstract.
10. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for agerelated macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119 (10): 1417–1436. Abstract.
11. Agerelated Eye Disease Study Group. Risk factors associated with agerelated macular degeneration. A casecontrol study in the agerelated eye disease study: AgeRelated Eye Disease Study Report Number 3. Ophthalmology 2000; 107 (12): 2224–2232. Abstract.
12. Gragoudas ES, Adamis AP, Cunningham ET jr et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. NEJM 2004; 351 (27): 2805–2816.
13. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group. Ranibizumab for neovascular agerelated macular degeneration. NEJM 2006; 355 (14): 1419–1431.
14. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration. Ophthalmology 2006; 113 (3): 363–372.
15. Arevalo JF, FromowGuerra J, Sanchez JG et al. PanAmerican Collaborative Retina Study Group. Primary intravitreal Bevacizumab for subfoveal choroidal neovascularization in agerelated macular degeneration: results of the PanAmerican Collaborative Retina Study Group at 12 months followup. Retina 2008; 28 (10): 1387–1394.
16. Karel I. Možnosti a ekonomické ukazatele léčby exsudativní věkem podmíněné makulární degenerace s choroidální neovaskulární membránou. Čes a slov oftal 2007; 5(63): 311–319.
17. Ernest J, Fišer I, Kolář P. Věkem podmíněná makulární degenerace (VPMD). 1. vyd. Praha: Česká vitreoretinální společnost 2007.
18. Fišer I. Léčba věkem podmíněné makulární degenerace. New EU Magazine of Medicine 2008; 3 (4): 13–22.
19. Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355 (14): 1419–1431.
20. D’Amico DJ for the VISION Clinical Trial Group. Results of the second year of Macugen for the treatment of neovascular AMD (VISION). Abstract presented at: American Society of Retinal Specialists Meeting; Montreal, July 16–20, 2005.
Labels
Geriatrics General practitioner for adultsArticle was published in
Czech Geriatric Review
2010 Issue 1-2
Most read in this issue
- Hypothyroidism in elderly
- The meaningfulness of life in the elderly
- Age-related macular degeneration
- Older age and allergy – is this an issue?